How Is Mesoblast Limited (ASX:MSB) Building on Its First Full Year of RYONCIL Sales?

Aditi Sarkar

04 November 2026 11:44 PM AEDT

How Is Mesoblast Limited (ASX:MSB) Building on Its First Full Year of RYONCIL Sales?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Mesoblast Limited (ASX:MSB) reported FY26 RYONCIL net product Revenue of USD 115 million following its first full year of commercial sales.
Fourth-quarter RYONCIL net revenue reached USD 36 million, showing the contribution from the U.S. treatment launch.
Total FY26 revenue reached approximately USD 120.3 million, compared with USD 17.2 million in FY25.
The company reported Gross Profit on total sales excluding Amortisation of approximately USD 110 million.
MSB continued Phase 3 studies and pursued additional indications, with future outcomes dependent on clinical and regulatory results.

Mesoblast Limited (ASX:MSB) develops allogeneic cellular medicines for serious inflammatory conditions. In its August 2026 financial results and operational update for the year ended 30 June 2026, MSB described a transition from clinical development toward commercial execution following the United States launch of RYONCIL. The first full sales year created a substantial product revenue stream while Clinical Trials for additional indications continued. Commercial uptake, Manufacturing execution and the cost of advancing the pipeline remain central to the FY27 outlook.

Commercial Revenue Becomes a Material Contributor

MSB reported RYONCIL net revenue of USD 115 million for FY26, including USD 36 million during the June quarter. The product was the principal contributor to total reported FY26 revenue of approximately USD 120.3 million, substantially above the USD 17.2 million recorded in the prior year. This change reflected the first full year of U.S. product commercialisation.

The presentation also reported approximately USD 110 million in gross profit on total sales before amortisation expense. That measure describes product Economics before the full range of commercial, development and corporate costs. It should therefore not be interpreted as consolidated net profit.

RYONCIL Distribution and Treatment Expansion

The reported sales period followed the U.S. rollout of RYONCIL for paediatric steroid-refractory acute graft-versus-host disease. MSB described its commercial infrastructure as including specialist sales personnel focused on hospitals and transplant centres. The company also highlighted distribution and manufacturing capabilities established to support product Supply as treatment Demand develops.

MSB has commenced a registration study assessing an expansion of RYONCIL into adults with steroid-refractory acute graft-versus-host disease. The company stated that enrolment was underway, with a planned network of up to 40 U.S. sites.

Clinical Pipeline Beyond the Initial Indication

The FY26 update described several clinical programs outside the initial RYONCIL indication. The U.S. regulator cleared an investigational new drug application for a paediatric Duchenne muscular dystrophy Phase 3 program. Separately, the company discussed work involving rexlemestrocel-L for chronic lower back pain associated with degenerative disc disease and inflammatory heart failure.

For chronic lower back pain, MSB reported that 350 patients had been treated in its Phase 3 program. Clinical milestones reflect research progress rather than proven commercial effectiveness in a newly targeted indication. Subsequent development decisions will depend on study outcomes, data analysis, regulatory discussions and the resources required for potential manufacturing expansion.

Funding Requirements and Execution Risks

The company reported net operating cash usage of USD 43.8 million during FY26 in its financial presentation. Growth in product sales may change the pattern of receipts, but commercial operations still involve distribution costs, manufacturing requirements and working capital. Clinical trial expenditure also continues alongside the newly established sales business.

MSB described the reinvestment of commercial proceeds into Phase 3 programs and manufacturing capacity. The balance between product revenue and development expenditure is relevant to future cash performance. Regulatory approvals for additional indications are not assured, and competitive, reimbursement and adoption factors may influence the commercial performance of its approved product.

Key Insights

MSB entered FY27 with its first substantial annual RYONCIL revenue contribution and an established U.S. commercial infrastructure. The reported figures indicate a significant change in the scale of operating activity, although gross profit from product sales is not equivalent to overall profitability.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.